APVO Form 4: Director Abdun-Nabi Daniel receives 7,200 RSUs

Rhea-AI Filing Summary

Abdun-Nabi Daniel, identified as a director of Aptevo Therapeutics, reported the grant of 7,200 Restricted Stock Units (RSUs) with a transaction date of 08/06/2025. The filing states the RSUs convert one-for-one into common stock of the issuer.

The RSUs are reported as directly owned following the grant and are set to vest in full on the first anniversary of the grant date. The Form 4 shows no sale or disposition associated with this reported transaction and lists beneficial ownership after the transaction as 7,200 shares (upon conversion).

Positive

• Grant of 7,200 RSUs to a director, with explicit 1:1 conversion into common stock and a clear vesting schedule (vests in full on first anniversary)

Negative

• None.

Insights

Compensation Analyst

TL;DR: Director grant of 7,200 RSUs vesting in one year; routine compensation disclosure with limited immediate market impact.

The Form 4 documents a standard equity-based compensation grant to a director: 7,200 RSUs that convert 1:1 into common shares and vest in full after one year. This is presented as direct ownership after the grant and contains no sale or disposition data. From a compensation perspective, the award follows common practice of time-based vesting to tie future value to continued service and company performance.

Corporate Governance Expert

TL;DR: Governance filing shows a typical director equity award; disclosure is complete on vesting schedule and conversion terms.

The filing clearly states the nature of the derivative award (RSUs), the conversion ratio (1:1), and that the RSUs vest in full on the first anniversary of grant. It also reports the post-transaction beneficial ownership as 7,200 shares. There are no indications in the form of dispositions, pledges, or indirect ownership claims related to these RSUs, so the disclosure is straightforward and specific to this grant.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Abdun-Nabi Daniel

(Last) (First) (Middle)

2401 4TH AVENUE

SUITE 1050

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	08/06/2025		A		7,200		(2)	(2)	Common Stock	7,200	$0	7,200	D

Explanation of Responses:

1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.

2. The RSUs vest in full on the first anniversary of the date of grant.

	/s/ SoYoung Kwon, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 for Aptevo (APVO) report?

The Form 4 reports a grant of 7,200 Restricted Stock Units (RSUs) to director Abdun-Nabi Daniel, with a transaction date of 08/06/2025.

How do the RSUs reported by APVO convert to common stock?

The filing states the RSUs convert one-for-one (1:1) into Aptevo common stock, $0.001 par value per share.

When do the 7,200 RSUs vest according to the filing?

The RSUs are disclosed to vest in full on the first anniversary of the grant date.

Does the Form 4 show any sale or disposition of shares by the reporting person?

No. The Form 4 shows the RSUs were acquired and reports 7,200 shares beneficially owned following the transaction; no dispositions are reported.

What ownership form is listed for the RSUs in the filing?

The Form 4 lists the ownership form as Direct (D) for the reported 7,200 RSUs/common shares following conversion.